Nexstim Oyj: Strategic Insights and Key Developments

NuWays AG has released an updated research report on Nexstim Oyj, maintaining a BUY recommendation with a target price of EUR 12 over 12 months. The report highlights Nexstim's promising advances, particularly at the European MidCap conference in Paris. The company focuses on navigated transcranial magnetic stimulation (nTMS) systems for both diagnostics and therapy.

In diagnostics, Brainlab's integration of nTMS into its neurosurgical workflow is seen as a significant advantage. This move aims to overcome barriers like additional vendor relationships and capital investment, thus facilitating adoption. Brainlab's extensive market presence supports this strategic shift.

Regarding therapy, Nexstim's revenue is transitioning as customers shift to reusable NBS 6 trackers. Therapy recurring sales, however, faced a temporary setback. Despite increased competition in therapy, Nexstim caters to premium markets, maintaining stable price levels for their systems.